12 Best Rising Penny Stocks To Buy
In this article, we will take a detailed look at the12 Best Rising Penny Stocks To Buy. For a quick overview of such stocks, read our article 5 Best Rising Penny Stocks To Buy. Stocks are roaring aft...
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
| 1.43 | |
| 1.5 | |
| - | |
| 1.5 | |
| 1.43 | |
| 0.765-2.34 | |
| 197 M | |
| 138 M | |
| 850 K | |
| -0.1 | |
| 0.708 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a detailed look at the12 Best Rising Penny Stocks To Buy. For a quick overview of such stocks, read our article 5 Best Rising Penny Stocks To Buy. Stocks are roaring aft...
Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top l...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: